Blood:抗CD43和抗CD44抗体涂层可在液体培养基中固定小鼠/人类造血干/祖细胞

2018-02-20 MedSci MedSci原创

中心点:抗CD43和抗CD44抗体涂层可固定活的小鼠和人类造血干细胞和祖细胞。抗体涂层可实现形成二维菌落、换液过程中无细胞识别丢失,并增加延时成像通量。摘要:示踪单个细胞识别是研究单个细胞行为动态的必要方法。高度运动的造血干细胞和祖细胞(HSPCs)移动迅速不易黏附,因此需要反复成像来保持细胞识别。更糟糕的是,HSPCs常在换液的过程中被洗脱。为克服上述限制,研究人员尝试以抗体涂层来降低体外HSP

中心点:

抗CD43和抗CD44抗体涂层可固定活的小鼠和人类造血干细胞和祖细胞。

抗体涂层可实现形成二维菌落、换液过程中无细胞识别丢失,并增加延时成像通量。

摘要:

示踪单个细胞识别是研究单个细胞行为动态的必要方法。高度运动的造血干细胞和祖细胞(HSPCs)移动迅速不易黏附,因此需要反复成像来保持细胞识别。更糟糕的是,HSPCs常在换液的过程中被洗脱。为克服上述限制,研究人员尝试以抗体涂层来降低体外HSPC的活性。

经实验发现,抗CD43和抗CD44抗体涂层可以浓度依赖性方式降低小鼠和人类的HSPCs的细胞活性。这使得在液体培养基中没有细胞混合情况下形成二维菌落,大大增加了延时成像通量,并且在换液过程中保持细胞位置。抗CD43,而非抗CD44抗体涂层,在浓度增加时,可减少小鼠HSPC增殖。抗体涂层对造血干细胞和多能祖细胞1-5(MPPs)的存活或粒细胞和巨核细胞系分化均无相关影响。各涂层对人类脐带CD34+的造血细胞的存活、增殖和分化也均无影响。

总而言之,利用抗体涂层,不仅可大大简化和加速对悬浮细胞的连续分析,还可使其在动态而非静态的培养条件下进行研究。

原始出处

Dirk Loeffler, et al. Mouse and human HSPC immobilization in liquid culture by CD43 or CD44-antibody coating.Blood  2018  :blood-2017-07-794131;  doi: https://doi.org/10.1182/blood-2017-07-794131

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864229, encodeId=a433186422928, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Jan 12 04:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935481, encodeId=3d4e193548191, content=<a href='/topic/show?id=c3264331d6' target=_blank style='color:#2F92EE;'>#CD44#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4331, encryptionId=c3264331d6, topicName=CD44)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Tue Nov 27 09:20:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494605, encodeId=cd2314946057c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Feb 22 03:20:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512440, encodeId=f3b31512440f3, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Thu Feb 22 03:20:00 CST 2018, time=2018-02-22, status=1, ipAttribution=)]
    2019-01-12 qidongfanjian
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864229, encodeId=a433186422928, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Jan 12 04:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935481, encodeId=3d4e193548191, content=<a href='/topic/show?id=c3264331d6' target=_blank style='color:#2F92EE;'>#CD44#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4331, encryptionId=c3264331d6, topicName=CD44)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Tue Nov 27 09:20:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494605, encodeId=cd2314946057c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Feb 22 03:20:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512440, encodeId=f3b31512440f3, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Thu Feb 22 03:20:00 CST 2018, time=2018-02-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1864229, encodeId=a433186422928, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Jan 12 04:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935481, encodeId=3d4e193548191, content=<a href='/topic/show?id=c3264331d6' target=_blank style='color:#2F92EE;'>#CD44#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4331, encryptionId=c3264331d6, topicName=CD44)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Tue Nov 27 09:20:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494605, encodeId=cd2314946057c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Feb 22 03:20:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512440, encodeId=f3b31512440f3, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Thu Feb 22 03:20:00 CST 2018, time=2018-02-22, status=1, ipAttribution=)]
    2018-02-22 俅侠
  4. [GetPortalCommentsPageByObjectIdResponse(id=1864229, encodeId=a433186422928, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Jan 12 04:20:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935481, encodeId=3d4e193548191, content=<a href='/topic/show?id=c3264331d6' target=_blank style='color:#2F92EE;'>#CD44#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4331, encryptionId=c3264331d6, topicName=CD44)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Tue Nov 27 09:20:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494605, encodeId=cd2314946057c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Feb 22 03:20:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512440, encodeId=f3b31512440f3, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Thu Feb 22 03:20:00 CST 2018, time=2018-02-22, status=1, ipAttribution=)]

相关资讯

Blood:活体内,SETD1A可保护HSCs避免激活诱导的功能性消耗。

中心点:ROS积累缺失的情况下,在HSCs和HPCs中,SETD1A调控DNA损伤和修复信号。SETD1A对接受原位炎症诱导HSC活化的小鼠的存活至关重要。摘要:造血干细胞(HSCs)的再生能力受DNA损伤积累限制。对H3K4甲基化转移酶(Setd1a)进行条件性诱变,发现HSCs的DNA损伤识别和修复通路的表达需要Setd1a的存在。特异性敲除成人的LT-HSCs(long-term-HSCs)

Clin Infect Dis:目前预防造血干细胞移植受体GNR相关菌血症耐药性的方法管用吗?

2017年发表在《Clin Infect Dis》的一项由以色列、意大利、荷兰、土耳其等国科学家进行的跨洲研究,考察了造血干细胞移植(HSCT)中革兰阴性杆菌(GNR)相关菌血症的抗菌药耐药性。

Stem cells:年老的造血干细胞可通过与年轻的干细胞相互作用而重返年轻!

在骨髓移植中,供体的年龄是一个重要的关注点,因为年老的造血干细胞(HSCs)移植效率相对较低。研究人员通过小鼠系统发现,年老的HSCs与年幼的间充质干细胞(MSCs)短暂的相互作用,可通过细胞间转移含有自噬相关的mRNAs的微型囊泡(MVs)而使年老的HSCs年轻化、恢复细胞功能,同时MSCs的AKT信号被激活,出现老化。激活的AKT会减少细胞微型囊泡内的自噬相关的mRNAs,并将miR-17和m

Blood:Hif-1α和Hif-2α参与调控血管内皮和造血干细胞的形成。

在发育过程中,造血干细胞(HSCs)是通过内皮细胞-造血性转变(EHT),由特殊的内皮细胞衍生而来,称为血管内皮细胞(HE)。已有报道体内缺氧诱导因子-1α(HIF-1α)可正性调控EHT,现研究人员对该过程可能存在其他的调控因子进行探究。Claudia Gerri等人发现,斑马鱼的Hif-2α也可以正性调控HSC形成。在携带hif-1aa;hif-1ab(hif-1α)和hif-2aa;hif-

Nature:利用细胞条形码技术追踪造血干细胞命运

在一项新的研究中,来自美国国家卫生研究院(National Institutes of Health, NIH)下属的国家心脏、肺与血液研究所(National Heart, Lung and Blood Institute, NHLBI)的研究人员通过给小鼠的骨髓细胞标记上遗传标签或者说条形码而能够追踪和描述单个血细胞在其天然环境中形成时的家族树。相关研究结果于2018年1月3日在线发表在Nat

Nature:利用细胞条形码技术可追踪造血干细胞命运

在一项新的研究中,来自美国国家卫生研究院(National Institutes of Health, NIH)下属的国家心脏、肺与血液研究所(National Heart, Lung and Blood Institute, NHLBI)的研究人员通过给小鼠的骨髓细胞标记上遗传标签或者说条形码而能够追踪和描述单个血细胞在其天然环境中形成时的家族树。相关研究结果于2018年1月3日在线发表在Nat